NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company and subsidiary of SciSparc Ltd., has completed manufacturing of its investigational product SCI-110 and secured the required batch release certification from a European Qualified Person (QP), a regulatory step that authorizes shipment of clinical trial material to participating study sites. The announcement, reported via NEWMEDIAWIRE, signals that the company can now move toward patient enrollment in its FDA-approved Phase IIb clinical trial evaluating SCI-110 for the treatment of Tourette Syndrome (TS) in adults.
The QP release is more than a procedural formality. Without it, clinical trial supplies cannot legally be shipped to sites in the three countries hosting the study: the Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. According to the company, all participating sites have completed site initiation activities and are prepared to receive drug supplies. The combination of site readiness and QP release removes a critical operational bottleneck, allowing NeuroThera to advance toward enrollment with investigational product shipments expected in the near term.
The milestone matters because Tourette Syndrome remains a condition with substantial unmet treatment needs. Current therapies often provide limited benefit or carry troublesome side effects, leaving room for new mechanisms of action. SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate that combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is designed to evaluate the efficacy, safety, and tolerability of SCI-110 in adults with TS. A successful trial could position the company within a therapeutic area that has attracted relatively little late-stage industry investment.
For investors, the announcement reduces near-term execution risk. Manufacturing and release failures are common causes of clinical trial delays, and completing this step keeps the program on its projected timeline. However, the company’s forward-looking statements acknowledge that actual performance may differ materially due to risks, including the ability to progress toward patient enrollment. As with any clinical-stage biopharmaceutical company, the pathway from trial initiation to regulatory approval remains uncertain and capital-intensive. Additional details on the company’s continuous disclosure documents are available on SEDAR+ at www.sedarplus.ca.
The broader implication is that NeuroThera is now entering a phase where clinical data, rather than logistics, will determine the program’s fate. Patient enrollment and subsequent readouts will be closely watched by both the scientific community and investors, as positive results could validate the cannabinoid-based approach for TS and open further development opportunities in central nervous system disorders.
